BiotechTube

IDE849 + durvalumab + IDE161

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Small-cell Lung Cancer

Conditions

Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3

Trial Timeline

Oct 14, 2025 → May 1, 2029

NCT ID
NCT07174583

About IDE849 + durvalumab + IDE161

IDE849 + durvalumab + IDE161 is a phase 1/2 stage product being developed by IDEAYA Biosciences for Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07174583. Target conditions include Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07174583Phase 1/2Recruiting

Competing Products

20 competing products in Small-cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
ALIMTA + CarboplatinEli LillyPhase 2
52
LazertinibYuhanPhase 1/2
41
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
CS-7017 + ErlotinibDaiichi SankyoPhase 1
33
Datopotamab Deruxtecan (Dato-DXd)Daiichi SankyoPhase 1/2
41
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + CorticosteroidDaiichi SankyoPhase 2
52
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXdDaiichi SankyoPhase 1/2
41
CS-7017 + Carboplatin + PaclitaxelDaiichi SankyoPhase 1
33
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Gocatamig + Atezolizumab + Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 1/2
41
Gilteritinib + ErlotinibAstellas PharmaPhase 1/2
41

Other Products from IDEAYA Biosciences

DarovasertibPhase 3
72
IDE196 + Crizotinib + Pembrolizumab + Ipilimumab + Nivolumab + DacarbazinePhase 2/3
60
DarovasertibPhase 2
47
IDE196 + Binimetinib + CrizotinibPhase 1/2
36
GSK4418959 + PD-1 inhibitorPhase 1/2
36